Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 243 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 190.52 | 07:27:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 190.52 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 19 | 243 | - | 189.52 - 319.76 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:06:08 | 3 | $ 191.00 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 27.69B | 145.36M | - | 9.84B | 1.16B | 7.99 | 23.85 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Biogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 204.23 | 205.24 | 189.52 | 194.29 | 1,221,938 | -13.71 | -6.71% |
| 1 Month | 221.30 | 221.50 | 189.52 | 205.58 | 1,116,405 | -30.78 | -13.91% |
| 3 Months | 247.36 | 251.99 | 189.52 | 220.08 | 1,201,370 | -56.84 | -22.98% |
| 6 Months | 263.45 | 268.74 | 189.52 | 232.58 | 1,151,061 | -72.93 | -27.68% |
| 1 Year | 292.88 | 319.76 | 189.52 | 255.76 | 1,086,319 | -102.36 | -34.95% |
| 3 Years | 269.55 | 468.2499 | 187.16 | 266.61 | 1,228,427 | -79.03 | -29.32% |
| 5 Years | 226.99 | 468.2499 | 187.16 | 269.79 | 1,386,788 | -36.47 | -16.07% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
